AbbVie Inc (ABBV): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

AbbVie ( ABBV) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.1%. By the end of trading, AbbVie rose $0.57 (1.1%) to $53.68 on average volume. Throughout the day, 6,911,729 shares of AbbVie exchanged hands as compared to its average daily volume of 6,251,600 shares. The stock ranged in a price between $52.52-$53.80 after having opened the day at $52.86 as compared to the previous trading day's close of $53.11. Other companies within the Drugs industry that increased today were: Aastrom Biosciences ( ASTM), up 25.2%, Sinovac Biotech ( SVA), up 17.1%, Bacterin International Holdings ( BONE), up 14.3% and EntreMed ( ENMD), up 12.6%.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $84.4 billion and is part of the health care sector. Shares are up 0.6% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate AbbVie a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and generally higher debt management risk.

On the negative front, Agenus ( AGEN), down 11.6%, Galmed Pharmaceuticals ( GLMD), down 8.7%, Dipexium Pharmaceuticals ( DPRX), down 8.3% and Durata Therapeutics ( DRTX), down 7.0% , were all laggards within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

AbbVie Is Likely to Correct: Book Some Profits

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst